Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others
Prescription Sales Recover But Marketing, One-Offs Have Impact
Executive Summary
Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.
You may also be interested in...
Hopes Rise For SK’s COVID-19 Vaccine As It Moves To Comparative Phase III Trial
Following positive interim Phase I/II results, expectations are rising for SK Bioscience’s recombinant COVID-19 vaccine as it becomes the first Korea-developed candidate to progress to Phase III.
Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.
Rising US Sales, EU Milestone Boost SK Bio's Q1
After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.